Rafael Pharmaceuticals to Present Late Breaking Data at the 2017 European Society for Medical Oncology (ESMO) Annual Meeting
September 08, 2017 07:00 ET
|
Rafael Pharmaceutical Inc.
Newark, NJ, Sept. 08, 2017 (GLOBE NEWSWIRE) -- BACKGROUND: Dr. Angela T. Alistar, Medical Director, GI Medical Oncology at Atlantic Health System Cancer Care, will lead a poster presentation at...
Cornerstone Pharmaceuticals, Inc. Announces Corporate Name Change to Rafael Pharmaceuticals, Inc.
June 05, 2017 11:00 ET
|
Cornerstone Pharmaceuticals
Newark, NJ, June 05, 2017 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a clinical-stage, oncology-focused pharmaceutical company, today announced that it is changing its corporate name to...
The Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified FOLFIRINOX in Patients with Metastatic Pancreatic Cancer
May 09, 2017 11:15 ET
|
Cornerstone Pharmaceuticals
Cranbury, NJ, May 09, 2017 (GLOBE NEWSWIRE) -- Cranbury, N.J., May 09, 2017 --(GlobeNewswire)-- Cornerstone Pharmaceuticals, Inc., a clinical-stage, oncology-focused pharmaceutical company, today...
StemPar Sciences Secures Initial Funding For Its Novel Cancer Metabolism Drugs
January 02, 2013 09:00 ET
|
Stempar Sciences
San Francisco, CA, Jan. 2, 2013 (GLOBE NEWSWIRE) -- Privately held StemPar Sciences, Inc. today announced an initial
investment from Troika Venture Capital, a multi-profile
international venture...